Drug-discoverer ImmuPharma says pre-clinical data has shown its IPP-204106 cancer drug can curb the growth of many human cancer cell lines.

The AIM-quoted company reports that data on this anti-cancer nucleolin antagonist (‘Nucant’) peptide confirm the ability of IPP-204106 compounds to ‘effectively control and stop the growth of a large panel of human cancer cell lines'. Collectively, the studies comprised breast cancer, prostate cancer, melanoma, leukaemia, colon cancer and pancreatic cancer cell lines.

London-based ImmuPharma says that ‘in vivo’ studies showed most tumours were completely eradicated and survival time increased without additional treatment. The company has filed patents covering many Nucant structures and initiated the regulatory studies needed to develop IPP-204106, while pursuing ‘grant opportunities from the French national research agencies’.

Chairman Richard Warr declares, ‘This exciting new drug has tremendous commercial potential if it meets its target profile of preventing tumour growth as well as metastasis while being non-toxic.’ Investors agree, having pushed the shares up 23.5p this morning to 80p, nearly twice their 12-month low of 44p and valuing the company at £58.2 million.

Growth Company Investor is the UK’s leading authority on small-cap and AIM companies. You can gain immediate access to all the recent share recommendations with no obligation, with a free 30-day trial. Click here to join today.

Immupharma	AIM	£29.06m	37.50p	0.00p
Click here for interactive charting
Other company articles:
ImmuPharma ponders funding			01/07/2008
ImmuPharma hails cancer progress			20/05/2008
Directors’ dealings by Andrew Hore			07/02/2008
A more palatable pill			05/10/2007
Turning point for shells			10/07/2006